| 05/15/2026 11:38 AM | Jade Biosciences (1798749) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/07/2026 4:26 PM | Jade Biosciences (1798749) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 05/07/2026 4:15 PM | Jade Biosciences (1798749) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 05/07/2026 4:20 PM | Jade Biosciences (1798749) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 05/07/2026 3:33 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 05/07/2026 3:35 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 04/28/2026 3:15 PM | Jade Biosciences (1798749) Filer | Form ARS | |
| 04/27/2026 3:12 PM | BlackRock, Inc. (2012383) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 04/22/2026 6:18 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/17/2026 3:18 PM | Jade Biosciences (1798749) Filer | Form PRE 14A | |
| 04/02/2026 3:10 PM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for JBIO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter.
|
| 03/06/2026 3:49 PM | Jade Biosciences (1798749) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/06/2026 3:34 PM | Jade Biosciences (1798749) Filer | Form POS EX | |
| 03/06/2026 3:36 PM | Jade Biosciences (1798749) Filer | Form POS EX | |
| 03/06/2026 3:26 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 03/06/2026 3:27 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 03/06/2026 3:15 PM | Jade Biosciences (1798749) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/06/2026 6:11 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 5:04 AM | Jade Biosciences (1798749) Subject Sofinnova Venture Partners X, L.P. (1680200) Filed by | Form SCHEDULE 13D/A | |
| 02/17/2026 5:11 PM | Jade Biosciences (1798749) Subject Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by | Form SCHEDULE 13G/A | |
| 02/13/2026 7:00 PM | Jade Biosciences (1798749) Issuer King Andrew James (1823187) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:00 PM | Frohlich Tom (1823925) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:00 PM | Balta Elizabeth (1884087) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:00 PM | Dahms Bradford D. (1787307) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:48 AM | Deep Track Capital, LP (1856083) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 01/05/2026 6:17 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/30/2025 11:15 PM | Jade Biosciences (1798749) Filer | Form EFFECT | |
| 12/22/2025 3:38 PM | Jade Biosciences (1798749) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
| 12/21/2025 11:15 PM | Jade Biosciences (1798749) Filer | Form EFFECT | |
| 12/19/2025 3:28 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 12/15/2025 6:11 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 7:18 AM | Deep Track Capital, LP (1856083) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 11/14/2025 6:00 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 6:13 AM | Jade Biosciences (1798749) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/17/2025 5:40 PM | BlackRock, Inc. (2012383) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 10/16/2025 6:35 PM | Jade Biosciences (1798749) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13G | |
| 10/08/2025 3:15 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Co-Invest IV L.P. (2042283) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Harwin Peter Evan (1663607) Reporting Jade Biosciences (1798749) Issuer Kiselak Tomas (1830177) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/08/2025 3:15 PM | Fairmount Funds Management LLC (1802528) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13D/A | |
| 10/07/2025 6:13 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/09/2025 6:13 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/13/2025 3:26 PM | Jade Biosciences (1798749) Filer | Form 8-A12B/A | |
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid |
| 07/29/2025 12:46 PM | Jade Biosciences (1798749) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G | |
| 07/17/2025 7:12 PM | BlackRock, Inc. (2012383) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G | |
| 07/14/2025 6:10 PM | Dahms Bradford D. (1787307) Reporting Jade Biosciences (1798749) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/14/2025 6:12 PM | Dahms Bradford D. (1787307) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2025 6:08 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/25/2025 4:31 PM | Atlas Venture Associates XII, L.P. (1845875) Reporting Jade Biosciences (1798749) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2025 4:37 PM | Atlas Venture Fund XII, L.P. (1812049) Reporting Jade Biosciences (1798749) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2025 3:59 PM | Atlas Venture Associates XII, L.P. (1845875) Reporting Jade Biosciences (1798749) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2025 4:03 PM | Atlas Venture Fund XII, L.P. (1812049) Reporting Jade Biosciences (1798749) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/20/2025 3:23 PM | Deep Track Capital, LP (1856083) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G | |
| 06/06/2025 9:03 AM | FMR LLC (315066) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G | |